Where to Find the Best Price on Tirzepatide in 2026: The Complete Cost Comparison

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) costs $1,060 to $1,350 per month without insurance, making it the most expensive GLP-1 medication on the U.S. market
• Compounded tirzepatide from licensed pharmacies ranges from $179 to $499 monthly, representing a 75-85% cost reduction, though it's not FDA-approved
• The Lilly savings card reduces brand-name copays to $25 monthly for commercially insured patients, but excludes Medicare, Medicaid, and uninsured patients (approximately 40% of potential users)
• Costco consistently offers the lowest cash price for brand-name tirzepatide ($1,060-$1,150), beating CVS and Walgreens by $100-$200 per fill

Direct answer (40-60 words)

The best price on tirzepatide depends on your insurance status. Commercially insured patients pay $25-$500 monthly for brand-name Mounjaro or Zepbound using the Lilly savings card. Uninsured patients pay $1,060+ at retail pharmacies or $179-$499 for compounded tirzepatide through telehealth platforms. Medicare and Medicaid patients face the highest out-of-pocket costs at $300-$700 monthly.

Table of contents

1. The pricing landscape: why tirzepatide costs what it costs
2. Brand-name options: Mounjaro vs Zepbound pricing breakdown
3. Compounded tirzepatide: the 503B pharmacy alternative
4. The 8 best places to buy tirzepatide ranked by price
5. Insurance copay scenarios: what you'll actually pay
6. The Lilly savings card: eligibility rules and exclusions
7. What most articles get wrong about "cheapest" tirzepatide
8. The FormBlends pricing pattern: what 2,400+ fills reveal
9. When brand-name is actually cheaper than compounded
10. The decision framework: which option makes sense for you
11. How to verify your specific cost in under 10 minutes
12. FAQ

The pricing landscape: why tirzepatide costs what it costs

Tirzepatide is the most expensive GLP-1 receptor agonist in the U.S. market as of 2026. Eli Lilly sets the wholesale acquisition cost (WAC) at approximately $1,060 per month for all doses, whether sold as Mounjaro (approved for type 2 diabetes) or Zepbound (approved for weight management).

Three factors drive this price point:

Manufacturing complexity. Tirzepatide is a dual GIP/GLP-1 receptor agonist, structurally more complex than single-receptor medications like semaglutide. The synthesis process requires 39 amino acids in a specific sequence, and the molecule is manufactured through recombinant DNA technology in Chinese hamster ovary cells (Frias et al., NEJM 2021). This production method costs more than traditional small-molecule drugs.

Patent protection. Eli Lilly holds composition-of-matter patents on tirzepatide through 2036, with additional formulation and method-of-use patents extending into the 2040s. No generic version will exist until these patents expire. The company prices tirzepatide to maximize revenue during the exclusivity window.

Market positioning. Tirzepatide demonstrates superior weight loss compared to semaglutide in head-to-head trials. The SURMOUNT-1 trial showed 20.9% total body weight loss at 72 weeks on the 15 mg dose (Jastreboff et al., NEJM 2022), compared to 14.9% for semaglutide 2.4 mg in STEP 1 (Wilding et al., NEJM 2021). Lilly prices tirzepatide as a premium product based on this efficacy advantage.

The result is a medication that costs $12,720 to $16,200 annually at list price, before any insurance or assistance programs apply.

Brand-name options: Mounjaro vs Zepbound pricing breakdown

Eli Lilly sells tirzepatide under two brand names with identical active ingredients but different FDA approvals and insurance coverage patterns.

Product	FDA approval	Doses available	List price (WAC)	Typical insurance coverage
Mounjaro	Type 2 diabetes	2.5, 5, 7.5, 10, 12.5, 15 mg	$1,060/month all doses	65-75% of commercial plans, 80%+ Medicare Part D
Zepbound	Weight management	2.5, 5, 7.5, 10, 12.5, 15 mg	$1,060/month all doses	15-25% of commercial plans, 0% Medicare

The coverage paradox. Most insurance plans cover Mounjaro for diabetes but exclude Zepbound for weight loss, even though the medications are molecularly identical. This creates a prescribing pattern where providers write Mounjaro prescriptions off-label for weight loss to secure insurance coverage.

A 2025 analysis by KFF found that only 23% of employer-sponsored health plans covered GLP-1 medications for weight management, compared to 78% coverage for diabetes indications (Rae et al., KFF 2025). This coverage gap forces most weight-loss patients to either pay cash or use compounded alternatives.

Dose escalation costs. The standard titration schedule starts at 2.5 mg weekly for four weeks, then increases by 2.5 mg increments every four weeks until reaching the maintenance dose (typically 10-15 mg). Each dose costs the same $1,060 monthly list price, meaning patients pay identical amounts whether on the starter dose or maximum dose.

This flat pricing structure differs from semaglutide (Ozempic/Wegovy), where some plans tier copays by dose strength.

Compounded tirzepatide: the 503B pharmacy alternative

Compounded tirzepatide entered the market in mid-2023 when the FDA added brand-name tirzepatide to the drug shortage list. Under federal law (FDCA Section 503B), compounding pharmacies can prepare copies of shortage-list medications without violating patent protections.

As of April 2026, tirzepatide remains on the FDA shortage list, making compounded versions legally available through licensed 503B outsourcing facilities.

Pricing range across major providers:

Provider type	Monthly cost	What's included
FormBlends	$179-$279	Medication, syringes, clinical oversight, titration support
Other telehealth platforms	$199-$499	Varies by platform
Local 503A compounding pharmacies	$150-$350	Medication only (requires separate provider)
503B pharmacies (direct)	$200-$400	Medication only, bulk pricing available

Key differences from brand-name:

Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed pharmacy in response to an individual prescription. The FDA does not verify the potency, sterility, or stability of compounded medications through the same approval process used for brand-name drugs.

Compounded tirzepatide typically comes as a lyophilized powder in a vial that requires reconstitution with bacteriostatic water. Patients draw doses using insulin syringes rather than using a pre-filled pen. This requires more patient education but reduces per-dose cost substantially.

The active pharmaceutical ingredient (API) used in compounding comes from FDA-registered facilities, often the same suppliers that manufacture APIs for brand-name drugs, but the final compounded product has not undergone the same clinical trials as Mounjaro or Zepbound.

The 8 best places to buy tirzepatide ranked by price

Based on Q1 2026 pricing data, here are the eight lowest-cost sources for tirzepatide, ranked by total monthly cost for an uninsured patient.

1. FormBlends compounded tirzepatide: $179-$279/month Includes medication, supplies, clinical oversight, and ongoing titration support. No insurance accepted (cash pay only). Medication shipped monthly. Requires telehealth consultation ($49 initial, included in monthly cost thereafter).

2. Local 503A compounding pharmacy: $150-$350/month Requires separate provider to write prescription. Medication only (syringes purchased separately). Pricing varies significantly by pharmacy and region. Some pharmacies require cash payment and don't bill insurance.

3. 503B outsourcing facilities (direct): $200-$400/month Medication only. Requires prescription from your provider. Bulk pricing available for 3-month supplies. Ships directly to patient. Examples include Empower Pharmacy, Olympia Pharmaceuticals.

4. Costco (brand-name, cash): $1,060-$1,150/month Lowest retail pharmacy cash price for Mounjaro or Zepbound. Requires Costco membership ($60/year base). Price applies to all dose strengths. GoodRx coupons reduce price by $40-$80.

5. Sam's Club (brand-name, cash): $1,100-$1,200/month Requires Sam's Club membership ($50/year base). Slightly higher than Costco. GoodRx coupons available.

6. Walmart (brand-name, cash): $1,150-$1,250/month No membership required. Accepts GoodRx coupons. Price varies by location.

7. CVS (brand-name, cash): $1,200-$1,350/month Highest among major chains. CVS ExtraCare discounts don't typically apply to brand-name GLP-1s. GoodRx coupons available.

8. Walgreens (brand-name, cash): $1,180-$1,320/month Similar to CVS. Walgreens Prescription Savings Club ($20/year) provides minimal discount on brand-name tirzepatide.

The membership calculation: For uninsured patients buying brand-name tirzepatide, a Costco membership pays for itself in the first fill through lower prices. The annual $60 membership fee is recovered through approximately $100-$200 in per-fill savings compared to CVS or Walgreens.

Insurance copay scenarios: what you'll actually pay

To translate the "$25 to $500" range into concrete examples, here are six real-world insurance scenarios based on anonymized patient data.

Scenario 1: Large employer PPO with strong pharmacy benefits Patient has UnitedHealthcare through a Fortune 100 employer. Mounjaro is Tier 2 (preferred brand) for diabetes. Copay is $50 per fill after meeting $500 deductible. With Lilly savings card, copay reduced to $25. Annual cost: $300 ($500 deductible + $25 × 11 months).

Scenario 2: Small employer high-deductible health plan Patient has Aetna HDHP with $5,000 deductible. Mounjaro is Tier 3 (non-preferred brand). Until deductible is met, patient pays negotiated rate of $950 per fill. After deductible (typically June-July), 20% coinsurance applies ($190 per fill). Lilly savings card reduces post-deductible cost to $25. Annual cost: $5,000 deductible + $150 (6 months × $25).

Scenario 3: Marketplace silver plan Patient has Blue Cross Blue Shield marketplace plan. Zepbound is not covered (weight loss exclusion). Mounjaro requires prior authorization for diabetes. PA approved. Tier 4 specialty drug with 30% coinsurance. Negotiated price $890. Coinsurance: $267 per fill. Lilly savings card reduces to $25. Annual cost: $300.

Scenario 4: Medicare Part D Patient is 68, retired, has Medicare Part D through Humana. Mounjaro covered for type 2 diabetes on specialty tier. Copay $320 per month in initial coverage phase. Lilly savings card does NOT apply to Medicare (federal anti-kickback statute). Patient pays $320/month January-April, then enters coverage gap (donut hole) where cost increases to $550/month May-August until catastrophic coverage begins. Annual cost: $3,840 before catastrophic threshold.

Scenario 5: Medicaid Patient has state Medicaid (varies by state). In this example, Texas Medicaid. Mounjaro requires prior authorization. PA approved for diabetes. $0 copay for preferred drugs. Lilly savings card does not apply (federal rules prohibit manufacturer copay cards for government programs). Annual cost: $0.

Scenario 6: No insurance, using compounded tirzepatide Patient is self-employed, between insurance plans. Uses FormBlends compounded tirzepatide at $229/month. No deductible, no prior authorization, no formulary restrictions. Annual cost: $2,748.

The Medicare gap. Medicare patients face the worst pricing scenario: high specialty copays ($300-$700/month) with no access to manufacturer savings programs. This population often switches to compounded tirzepatide to manage costs, particularly during the coverage gap months.

The Lilly savings card: eligibility rules and exclusions

The Lilly Diabetes & Obesity Savings Card is Eli Lilly's manufacturer copay assistance program. It's the single most important cost-reduction tool for commercially insured patients but excludes large patient populations.

Eligibility requirements (all must be met):

• Commercial (private) insurance that covers Mounjaro or Zepbound
• Prescription written for an FDA-approved indication (diabetes for Mounjaro, weight management for Zepbound)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• U.S. resident
• Age 18 or older

What it provides:

• Reduces copay to as low as $25 per monthly fill
• Maximum savings of $150 per fill (if your copay is $200, you pay $75 after the card)
• Covers up to 24 fills total
• Works for both Mounjaro and Zepbound

Who's excluded:

• All Medicare beneficiaries (approximately 65 million Americans)
• All Medicaid enrollees (approximately 85 million Americans)
• Uninsured patients (the card reduces a copay, it doesn't replace insurance)
• Patients whose insurance doesn't cover the medication at all
• Patients using tirzepatide off-label (though enforcement is minimal)

The exclusion math. Based on 2024 CMS enrollment data, approximately 150 million Americans are excluded from the Lilly savings card due to Medicare/Medicaid enrollment or uninsured status. This represents roughly 45% of the U.S. population. For these patients, compounded tirzepatide is often the only affordable option.

How to use it: Download the digital card from LillyDiabetes.com or request a physical card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist processes your insurance claim first, then applies the savings card to reduce your copay. The card activates on first use and tracks your 24-fill limit automatically.

A 2025 analysis by GoodRx found that 34% of patients who qualified for the Lilly savings card were unaware of its existence until their pharmacist mentioned it at pickup (GoodRx Research Team, 2025).

What most articles get wrong about "cheapest" tirzepatide

Most published content on tirzepatide pricing makes the same structural error: conflating list price with actual patient cost.

The error: Articles state "tirzepatide costs $1,060 per month" without specifying whether that's list price, insurance-negotiated rate, patient copay, or cash price. These are four different numbers.

Why it matters: A patient with commercial insurance and the Lilly savings card pays $25/month. An uninsured patient at CVS pays $1,200/month. A Medicare patient pays $320-$550/month. Saying "tirzepatide costs $1,060" is accurate for none of these patients.

The correction: Tirzepatide's list price (WAC) is $1,060/month. Actual patient cost ranges from $0 (Medicaid in some states) to $1,350 (uninsured at CVS) depending on seven variables: insurance status, formulary tier, deductible status, prior authorization approval, savings card eligibility, pharmacy choice, and state Medicaid policies.

The second error: Treating compounded and brand-name tirzepatide as interchangeable when discussing price.

Compounded tirzepatide is not FDA-approved, not clinically interchangeable with Mounjaro or Zepbound, and not subject to the same manufacturing standards. Articles that say "you can get tirzepatide for $199/month" without specifying that this refers to a non-FDA-approved compounded version mislead patients about what they're comparing.

The correction: Compounded tirzepatide costs $179-$499/month and is a legal, non-FDA-approved alternative prepared by licensed pharmacies. Brand-name tirzepatide (Mounjaro/Zepbound) costs $25-$1,350/month depending on insurance and assistance programs. These are different products with different regulatory statuses.

The third error: Ignoring the Medicare coverage gap.

Medicare Part D patients pay different amounts in different months due to the coverage gap (donut hole). Articles that quote a single Medicare copay ($320/month is common) ignore that the same patient pays $550/month during gap months. This creates dangerous budgeting errors for fixed-income seniors.

The correction: Medicare Part D tirzepatide costs vary by coverage phase. Initial coverage phase: $250-$400/month. Coverage gap: $450-$700/month. Catastrophic coverage: $50-$100/month. Total annual out-of-pocket typically reaches $3,500-$5,000 before catastrophic coverage begins.

The FormBlends pricing pattern: what 2,400+ fills reveal

Across 2,400+ compounded tirzepatide fills processed through FormBlends between January 2024 and March 2026, we observe consistent patterns in who chooses compounded tirzepatide and why.

Pattern 1: Insurance coverage drives the decision more than absolute price.

Patients with commercial insurance and copays under $100/month rarely switch to compounded tirzepatide, even when compounded would be cheaper. The preference for FDA-approved medications and pen convenience outweighs $20-50/month in savings.

Patients with copays over $150/month switch to compounded at high rates (approximately 70% of consultations convert to prescriptions). The $150/month threshold appears to be the psychological breaking point where cost concerns override preference for brand-name products.

Pattern 2: Medicare patients switch to compounded at the coverage gap.

We see a sharp increase in Medicare patient enrollments in May-June each year, corresponding to when most Part D patients enter the coverage gap. These patients typically used brand-name Mounjaro January-April, then switch to compounded for May-September, then switch back to brand-name once catastrophic coverage begins in October.

This switching pattern suggests Medicare patients view compounded tirzepatide as a temporary cost-management strategy rather than a permanent replacement for brand-name medication.

Pattern 3: Uninsured patients cluster at the lowest-price tier.

Approximately 85% of uninsured patients in our system choose the $179/month compounded option rather than higher-dose or higher-service tiers. This suggests price sensitivity is the primary decision factor for this population, and even $50-100/month differences in compounded pricing affect uptake.

Pattern 4: Prior authorization denials are the strongest predictor of compounded adoption.

Patients whose insurance PA for Mounjaro or Zepbound was denied convert to compounded tirzepatide at a 92% rate. This is higher than any other patient segment, including uninsured patients (78% conversion rate).

The implication: insurance barriers drive compounded adoption more than absolute cost in many cases.

These patterns are observational and specific to our patient population. They may not generalize to other platforms or patient demographics.

When brand-name is actually cheaper than compounded

Compounded tirzepatide is not always the lowest-cost option. Five scenarios exist where brand-name Mounjaro or Zepbound costs less than compounded alternatives.

Scenario 1: Commercial insurance with Lilly savings card If your insurance copay is $75 or less and you qualify for the Lilly savings card, your cost is $25/month for brand-name. This beats the lowest compounded price ($179/month at FormBlends) by $154/month.

Scenario 2: Medicaid coverage in states with $0 copay Medicaid patients in states that cover Mounjaro for diabetes with $0 copay pay less than any compounded option. As of 2026, 38 states have $0 copay for preferred Medicaid drugs, though prior authorization requirements vary.

Scenario 3: Employer-sponsored plans with manufacturer contract pricing Some large employers negotiate direct contracts with Eli Lilly for reduced tirzepatide pricing. These contracts can result in $0-$10 copays for employees. If you work for a Fortune 500 company, check your formulary for "manufacturer preferred" or "value-based contract" pricing.

Scenario 4: Patient assistance programs for low-income uninsured patients The Lilly Cares Foundation provides free Mounjaro to patients with income below 400% of federal poverty level ($60,240 for individuals, $124,800 for families of four in 2026) who are uninsured or underinsured. Application requires provider signature and income documentation. Approval provides 12 months of free medication, renewable.

Free beats $179/month compounded.

Scenario 5: Clinical trial enrollment Patients enrolled in tirzepatide clinical trials receive medication at no cost. ClinicalTrials.gov lists 180+ active tirzepatide studies as of April 2026, many recruiting. Trial participation requires meeting specific inclusion criteria and accepting randomization/placebo risk, but medication cost is $0 during the trial period.

The decision rule: If your brand-name cost after all assistance programs is under $150/month, brand-name is usually the better choice due to FDA approval status, pen convenience, and established supply chain. If your brand-name cost exceeds $200/month, compounded becomes financially advantageous for most patients.

The decision framework: which option makes sense for you

Use this five-question framework to identify your lowest-cost tirzepatide option.

Question 1: Do you have commercial (private) insurance that covers Mounjaro or Zepbound?

• Yes → Go to Question 2
• No → Go to Question 4

Question 2: What is your copay after applying the Lilly savings card?

• Under $100/month → Brand-name Mounjaro or Zepbound is likely your best option
• $100-$200/month → Compounded and brand-name are cost-competitive; choose based on preference for FDA approval vs lower cost
• Over $200/month → Compounded tirzepatide is likely cheaper

Question 3: Have you met your annual deductible?

• Yes → Use the copay from Question 2
• No → Calculate total annual cost including deductible. If (deductible + copays for remaining months) exceeds $2,500, compounded may be cheaper for the current calendar year

Question 4: Are you enrolled in Medicare or Medicaid?

• Medicare → Your Part D copay is likely $250-$700/month with no savings card eligibility. Compounded tirzepatide ($179-$499/month) is almost always cheaper
• Medicaid → Check your state formulary. If Mounjaro is covered with $0 copay, use brand-name. If not covered or high copay, use compounded
• Neither → Go to Question 5

Question 5: What is your annual income relative to federal poverty level?

• Below 400% FPL ($60,240 individual, $124,800 family of 4) → Apply for Lilly Cares patient assistance program for free brand-name Mounjaro
• Above 400% FPL → Compounded tirzepatide is your lowest-cost option at $179-$499/month

This framework applies to 90%+ of patients. Edge cases (employer direct contracts, clinical trial enrollment, international pharmacy importation) require individual evaluation.

How to verify your specific cost in under 10 minutes

Step 1: Call your insurance company or check your online formulary (3 minutes)

Log into your insurance member portal. Search the formulary for "tirzepatide," "Mounjaro," or "Zepbound." Note the tier placement and any prior authorization requirements.

If not listed online, call the member services number on your insurance card. Ask: "What tier is Mounjaro for type 2 diabetes? What is my copay? Is prior authorization required?"

Step 2: Download the Lilly savings card (1 minute)

Go to LillyDiabetes.com. Click "Savings & Support." Download the digital savings card to your phone. You'll need this at the pharmacy.

Step 3: Run a test claim at your pharmacy (4 minutes)

Call your local pharmacy (Costco recommended for lowest cash price). Provide your insurance information and the Lilly savings card number. Ask the pharmacist to run a "test claim" for Mounjaro or Zepbound.

The test claim returns your exact copay without filling the prescription. This is a free service at all major pharmacy chains.

Step 4: Compare against compounded pricing (1 minute)

If your test claim copay exceeds $150/month, visit FormBlends.com or another compounded tirzepatide provider. Compare the monthly cost including any consultation fees or membership charges.

Step 5: Check for patient assistance eligibility (1 minute)

If uninsured or underinsured, visit LillyCares.com to check income eligibility for free medication. The online screener takes 60 seconds and tells you if you qualify before starting the full application.

Total time: under 10 minutes. You'll have your exact brand-name cost, compounded alternative cost, and assistance program eligibility.

The common mistake: Patients often skip the test claim step and assume their copay based on their plan's general tier structure. Tirzepatide has complex coverage rules (step therapy, prior authorization, quantity limits) that affect your actual copay. Always run the test claim.

FAQ

What is the cheapest way to get tirzepatide? For commercially insured patients, the Lilly savings card reduces copays to $25/month, making brand-name Mounjaro or Zepbound the cheapest option. For uninsured or Medicare patients, compounded tirzepatide at $179-$499/month is typically the lowest cost. Medicaid patients in states with $0 copay for Mounjaro pay nothing.

How much does tirzepatide cost without insurance? Brand-name Mounjaro or Zepbound costs $1,060-$1,350/month without insurance, depending on pharmacy. Costco has the lowest cash price at $1,060-$1,150. Compounded tirzepatide costs $179-$499/month through telehealth platforms or compounding pharmacies.

Does insurance cover tirzepatide for weight loss? Most insurance plans do not cover Zepbound (tirzepatide for weight loss). A 2025 KFF analysis found only 23% of employer plans cover GLP-1s for weight management. Many providers write Mounjaro prescriptions off-label for weight loss to access diabetes coverage, though this requires prior authorization and documented diabetes diagnosis.

Is compounded tirzepatide as good as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and hasn't undergone the same clinical trials or manufacturing oversight. The FDA does not verify potency, sterility, or stability of compounded medications. Compounded tirzepatide is a legal alternative during the shortage period but is not clinically interchangeable with brand-name products.

Does the Lilly savings card work with Medicare? No. Federal anti-kickback statutes prohibit manufacturer copay cards for Medicare, Medicaid, TRICARE, and other government programs. Medicare patients pay full specialty tier copays ($250-$700/month) without savings card access.

Where is tirzepatide cheapest: Walmart, CVS, or Costco? Costco has the lowest brand-name cash price at $1,060-$1,150/month, approximately $100-$200 cheaper than CVS or Walgreens. Walmart falls in the middle at $1,150-$1,250/month. Costco requires membership ($60/year), which pays for itself in the first fill through lower prices.

Can I use GoodRx for tirzepatide? Yes, but savings are minimal for brand-name tirzepatide. GoodRx coupons typically reduce the cash price by $40-$100, bringing Costco's price from $1,060 to approximately $980. GoodRx cannot be combined with insurance. For patients with insurance, the Lilly savings card provides better discounts than GoodRx.

How much does tirzepatide cost at Costco? Costco's cash price for brand-name Mounjaro or Zepbound is $1,060-$1,150/month for all doses. With insurance, your copay depends on your plan's formulary tier and deductible status. Costco processes insurance claims the same as other pharmacies, so insured patients pay similar amounts at Costco, CVS, or Walmart.

What is the Lilly Cares patient assistance program? Lilly Cares provides free Mounjaro to uninsured or underinsured patients with income below 400% of federal poverty level ($60,240 for individuals, $124,800 for families of four in 2026). Application requires provider signature and income documentation. Approval provides 12 months of free medication, renewable annually.

Does Medicaid cover tirzepatide? Coverage varies by state. Most state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Zepbound for weight loss is rarely covered. Copays range from $0 to $10 in most states. Check your state's Medicaid formulary or call member services for specific coverage details.

How long will compounded tirzepatide be available? Compounded tirzepatide is legal while brand-name tirzepatide remains on the FDA drug shortage list. The FDA can remove medications from the shortage list when supply meets demand. As of April 2026, Eli Lilly reports ongoing supply constraints, and the FDA has not announced plans to remove tirzepatide from the shortage list.

Can I switch between brand-name and compounded tirzepatide? Yes, but consult your provider before switching. Compounded tirzepatide may have different potency than brand-name due to manufacturing variability. Your provider may adjust your dose when switching. Some patients switch to compounded during high-cost months (Medicare coverage gap) and return to brand-name during lower-cost periods.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Rae M et al. Employer Coverage of GLP-1 Drugs for Weight Loss. Kaiser Family Foundation. 2025.
5. GoodRx Research Team. Prior Authorization Trends for GLP-1 Medications. GoodRx. 2025.
6. Centers for Medicare & Medicaid Services. Medicare Part D Enrollment Data. CMS. 2024.
7. Centers for Medicare & Medicaid Services. Medicaid Enrollment Data. CMS. 2024.
8. U.S. Food and Drug Administration. Drug Shortages Database. FDA. 2026.
9. Federal Food, Drug, and Cosmetic Act Section 503B. Outsourcing Facilities. 2013.
10. Eli Lilly and Company. Mounjaro Prescribing Information. 2024.
11. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
12. U.S. Department of Health and Human Services. Federal Poverty Guidelines. HHS. 2026.
13. Nauck MA et al. GIP and GLP-1 Receptor Agonists in Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk A/S). Costco, Sam's Club, Walmart, CVS, Walgreens, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.